Skip to main content

Table 1 Baseline predictors and outcomes in the Emirati validation and Framingham cohorts

From: Performance of the Framingham coronary heart disease risk score for predicting 10-year cardiac risk in adult United Arab Emirates nationals without diabetes: a retrospective cohort study

Characteristic Emirati validation cohort (n = 554) Framingham study cohort* (n = 5251) P-value†
Age (years), mean (SD) 48.0 (12.8) 49.0 (NA)  
Men, n (%) 249 (44.9) 2439 (46.4) 0.502
Blood pressure, n (%)
 Normal and prehypertension 408 (73.7) 3558 (67.7) <  0.001
 Stage 1 HTN 116 (20.9) 1095 (20.9)  
 Stage 2 HTN 30 (5.4) 598 (11.4)  
TC, mmol/L, n (%)
  < 5.17 298 (53.8) 1996 (38.0) <  0.001
 5.17–6.18 166 (30.0) 1879 (35.8)  
  ≥ 6.20 90 (16.2) 1376 (26.2)  
HDL-C, mmol/L, n (%)
  ≤ 1.53 482 (87.0) 3829 (72.9) <  0.001
  ≥ 1.55 72 (13.0) 1422 (27.1)  
Smoking history, n (%) 102 (18.4) 2045 (38.9) <  0.001
Diabetes mellitus, n (%) 0 (0.0)‡ 234 (4.5) <  0.001
Observed hCHD events, n (%) 26 (4.7) 273 (5.2)  
  1. NA, not available; HTN, hypertension; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; hCHD, hard coronary heart disease; SD, standard deviation; FRS, Framingham risk score
  2. *Data retrieved from D’Agostino et al. [10]
  3. P-values for categorical variables were calculated using Fisher’s exact test (2-tailed)
  4. ‡The FRS hCHD model is not intended for patients with diabetes, therefore excluded from the study